Currently, there are 42.45M common shares owned by the public and among those 40.53M shares have been available to trade.
Insiders at the company have transacted a total of 59 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 35 of these insider trades were purchases, accounting for 251,836 shares. Insider sales of the common stock occurred on 24 occasions, with total insider shares sold totaling 81,171 shares.
The company’s stock has a 5-day price change of 7.29% and 84.03% over the past three months. AXGN shares are trading 55.20% year to date (YTD), with the 12-month market performance up to 17.65% higher. It has a 12-month low price of $3.45 and touched a high of $10.62 over the same period. AXGN has an average intraday trading volume of 490.27K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.38%, 27.39%, and 45.62% respectively.
Institutional ownership of Axogen Inc. (NASDAQ: AXGN) shares accounts for 75.65% of the company’s 42.45M shares outstanding.
It has a market capitalization of $456.22M and a beta (3y monthly) value of 1.06. The earnings-per-share (ttm) stands at -$0.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.39% over the week and 3.87% over the month.
Analysts forecast that Axogen Inc. (AXGN) will achieve an EPS of $Axon Enterprise, Inc. for the current quarter, $269.80 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Align Technology, Inc. while analysts give the company a high EPS estimate of $AxoGen, Inc. Comparatively, EPS for the current quarter was $ASGN Incorporated a year ago. Earnings per share for the fiscal year are expected to increase by 40.08%, and 86.07% over the next financial year.
Looking at the support for the AXGN, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on November 11, 2022, with the firm’s price target at $15.
